Evidence map›Paper›PMID 30013539›Full record

ReviewFrontiers in microbiology2018

Nano-Strategies to Fight Multidrug Resistant Bacteria-"A Battle of the Titans".

Pedro V Baptista, Matthew P McCusker, Andreia Carvalho, Daniela A Ferreira, Niamh M Mohan, Marta Martins, Alexandra R Fernandes

Abstract readReview
In one paragraph

Review in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 297 papers.

0numbers the graph read from it
0cells of the map it votes in
297citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

297 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Effect of Biosynthesized Gold and Silver Nanoparticles UsingAntibiotics (Basel, Switzerland) · 2026
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Alkanna tinctoria extract-mediated biomass synthesis of Ag-ZnO nanoparticles: characterization, antimicrobial and antibiofilm activities.International microbiology : the official journal of the Spanish Society for Microbiology · 2025
    Article

237 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Pedro V BaptistaUCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal.
Matthew P McCuskerSchool of Food Science and Environmental Health, College of Sciences and Health, Dublin Institute of Technology, Dublin, Ireland.
Andreia CarvalhoUCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal.
Daniela A FerreiraDepartment of Microbiology, Moyne Institute of Preventive Medicine, Schools of Genetics and Microbiology, Trinity College Dublin, University of Dublin, Dublin, Ireland.
Niamh M MohanDepartment of Microbiology, Moyne Institute of Preventive Medicine, Schools of Genetics and Microbiology, Trinity College Dublin, University of Dublin, Dublin, Ireland.
Marta MartinsDepartment of Microbiology, Moyne Institute of Preventive Medicine, Schools of Genetics and Microbiology, Trinity College Dublin, University of Dublin, Dublin, Ireland.
Alexandra R FernandesUCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Caparica, Portugal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infectious diseases remain one of the leading causes of morbidity and mortality worldwide. The WHO and CDC have expressed serious concern regarding the continued increase in the development of multidrug resistance among bacteria. Therefore, the antibiotic resistance crisis is one of the most pressing issues in global public health. Associated with the rise in antibiotic resistance is the lack of new antimicrobials. This has triggered initiatives worldwide to develop novel and more effective antimicrobial compounds as well as to develop novel delivery and targeting strategies. Bacteria have developed many ways by which they become resistant to antimicrobials. Among those are enzyme inactivation, decreased cell permeability, target protection, target overproduction, altered target site/enzyme, increased efflux due to over-expression of efflux pumps, among others. Other more complex phenotypes, such as biofilm formation and quorum sensing do not appear as a result of the exposure of bacteria to antibiotics although, it is known that biofilm formation can be induced by antibiotics. These phenotypes are related to tolerance to antibiotics in bacteria. Different strategies, such as the use of nanostructured materials, are being developed to overcome these and other types of resistance. Nanostructured materials can be used to convey antimicrobials, to assist in the delivery of novel drugs or ultimately, possess antimicrobial activity by themselves. Additionally, nanoparticles (e.g., metallic, organic, carbon nanotubes, etc.) may circumvent drug resistance mechanisms in bacteria and, associated with their antimicrobial potential, inhibit biofilm formation or other important processes. Other strategies, including the combined use of plant-based antimicrobials and nanoparticles to overcome toxicity issues, are also being investigated. Coupling nanoparticles and natural-based antimicrobials (or other repurposed compounds) to inhibit the activity of bacterial efflux pumps; formation of biofilms; interference of quorum sensing; and possibly plasmid curing, are just some of the strategies to combat multidrug resistant bacteria. However, the use of nanoparticles still presents a challenge to therapy and much more research is needed in order to overcome this. In this review, we will summarize the current research on nanoparticles and other nanomaterials and how these are or can be applied in the future to fight multidrug resistant bacteria.

Indexed as

antimicrobial resistancemultidrug resistancenanomaterialsnanoparticlesnanotheranosticsnovel antimicrobial agentsplant-based compounds

Identifiers

PMID30013539
PMCPMC6036605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.